Vascular Biogenics Ltd.
Vascular Biogenics Ltd. (also known as VBL Therapeutics), is a clinical stage biotechnology company. It is engaged in development and commercialization of innovative treatments for immuno-inflammatory diseases and cancer. The company has developed Lecinoxoid class of oral anti-inflammatory agents for chronic inflammatory diseases, such as Psoriasis, Rheumatoid Arthritis (RA), Inflammatory Bowel Diseases (IBD), Multiple Sclerosis (MS) and Atherosclerosis. A Phase II efficacy and safety study is currently underway to evaluate VB-201 for the treatment of patients with psoriasis. VBL is also conducting a Phase 2 clinical trial to evaluate the effect of VB-201 in patients with elevated high sensitivity C-reactive protein (hsCRP) who are currently taking statins. It has also developed the Vascular Targeting System, a new platform technology for the formation of new blood vessels, a fundamental factor in the development of cancer and other pathological diseases. VBL has recently started Phase II clinical trials for VB-111 product candidate which is used in the treatment of thyroid cancer and glioblastoma. VBL has more than 70 granted patents and more than 110 applicatioins pending. The company is headquartered in Or Yehuda, Israel.